Lesopitron Explained

Lesopitron (E-4424) is a selective full agonist of the 5-HT1A receptor which is structurally related to the azapirones.[1] In 2001 it was under development by Esteve as an anxiolytic for the treatment of generalized anxiety disorder (GAD).[2] [3] It made it to phase II clinical trials but was apparently discontinued as no new information on lesopitron has surfaced since.[2] [3]

See also

Notes and References

  1. Haj-Dahmane S, Jolas T, Laporte AM, etal . Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat . European Journal of Pharmacology . 255 . 1–3 . 185–96 . April 1994 . 8026543 . 10.1016/0014-2999(94)90097-3.
  2. Micheli F . Lesopitron (Esteve) . IDrugs: The Investigational Drugs Journal . 4 . 2 . 218–24 . February 2001 . 16032484 .
  3. Fresquet A, Sust M, Lloret A, etal . Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder . The Annals of Pharmacotherapy . 34 . 2 . 147–53 . February 2000 . 10676820 . 10.1345/aph.19041 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lesopitron".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.